Triggering cell death in metastatic melanoma may pave the way for new cancer treatments

Cancer research · Melanoma

In metastatic melanoma cells that have spread to lymph nodes, the protein ferroptosis suppressor protein 1 (FSP1) provides a critical defense against cell death; inhibiting FSP1 with novel small‑molecule inhibitors sharply reduces tumor growth in vivo.

A study published in Nature used mouse models to demonstrate that metastatic melanoma cells that have entered lymph nodes rely on the antioxidant protein FSP1 to prevent ferroptosis, a form of cell death driven by lipid oxidation. By delivering new FSP1‑inhibiting compounds directly to the lymph‑node tumors, researchers observed a pronounced shrinkage in tumor growth, whereas the same inhibitors had little effect when tested on melanoma cells cultured in vitro. These findings highlight a previously underappreciated tissue‑context dependence of ferroptosis in cancer and suggest that targeting FSP1 could provide a therapeutic strategy against metastatic melanoma.

The discovery that metastatic melanoma cells in lymph nodes are uniquely dependent on FSP1 to evade ferroptosis offers a new vulnerability that can be exploited therapeutically. Targeting this pathway could slow the progression of metastatic disease and improve outcomes for patients whose cancer has spread to lymphatic tissue.

Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Original source

Related signals